Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right

For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or not suitable for transplant. A meta-analysis presenting head-to-head comparisons of cardiac transplant versus LVAD as destination therapy (LVAD-DT) found no difference in 1-year mortality rates between LVAD-DT and cardiac transplant (OR 1.49; 95% CI [0.48–4.66]; I2=82.8%). Moreover, a recent subanalysis from the Interagency Registry for Mechanically Assisted Circulatory Support found similar outcomes after LVAD-DT implantation in both transplant and non-transplant centres. The time is right for LVAD-DT in non-transplant centres, provided multidisciplinary heart failure teams and expertise are in place

The 4q25 variant rs13143308T links risk of atrial fibrillation to defective calcium homeostasis

Aims: Single nucleotide polymorphisms on chromosome 4q25 have been associated with risk of atrial fibrillation (AF) but the exiguous knowledge of the mechanistic links between these risk variants and underlying electrophysiological alterations hampers their clinical utility. Here, we here tested the hypothesis that 4q25 risk variants cause alterations in the intracellular calcium homeostasis that predispose to spontaneous electrical activity. Methods and results: Western blotting, confocal calcium imaging, and patch-clamp techniques were used to identify mechanisms linking the 4q25 risk variants rs2200733T and rs13143308T to defects in the calcium homeostasis in human atrial myocytes. Our findings revealed that the rs13143308T variant was more frequent in patients with AF and that myocytes from carriers of this variant had a significantly higher density of calcium sparks (14.1±4.5 vs. 3.1±1.3 events/min, p¿=¿0.02), frequency of transient inward (ITI) currents (1.33±0.24 vs. 0.26±0.09 events/min, p¿<¿0.001) and incidence of spontaneous membrane depolarizations (1.22±0.26 vs. 0.56±0.17 events/min, p¿=¿0.001) than myocytes from patients with the normal rs13143308G variant. These alterations were linked to higher sarcoplasmic reticulum calcium loading (10.2±1.4 vs. 7.3±0.5amol/pF, p¿=¿0.01), SERCA2 expression (1.37±0.13 fold, p¿=¿0.03) and RyR2 phosphorylation at s2808 (0.67±0.08 vs. 0.47±0.03, p¿=¿0.01) but not at s2814 (0.28±0.14 vs. 0.31±0.14, p¿=¿0.61) in patients carrying the rs13143308T risk variant. Furthermore, the presence of a risk variant or AF independently increased the ITI frequency and the increase in the ITI frequency observed in carriers of the risk variants was exacerbated in those with AF. By contrast, the presence of a risk variant did not affect the amplitude or properties of the L-type calcium current in patients with or without AF. Conclusions: We here identify the 4q25 variant rs13143308T as a genetic risk marker for AF, specifically associated with excessive calcium release and spontaneous electrical activity linked to increased SERCA2 expression and RyR2 phosphorylationThis work was supported by multi-centric grants from Centro Nacional de Investigaciones Cardiovasculares [CNIC-2009-08 to L.H.-M. and D.F.]; a grant from Fundacio´ Marato´ TV3 [2015-20-30 to L.H.-M.]; and grants from the Spanish Ministry of Economy and Competition [SAF2014-58286-C2-1-R to L.H.-M.] and [DPI2013-44584-R to R.B.]; and from the Spanish Ministry of Health and Consume, Instituto de Salud Carlos III, Red de Investigacio´n Cardiovascular [RD12/0042/0002] and CIBERCV to J.C., and from Fondo Europeo de Desarrollo Regional (FEDER)

First-in-human PeriCord cardiac bioimplant : scalability and GMP manufacturing of an allogeneic engineered tissue graft

Altres ajuts: La Marató de TV3 Foundation, Government of Catalonia, Catalan Society of Cardiology, "La Caixa" Banking Foundation, Spanish Ministry of Science, Innovation and Universities, Institute of Health Carlos III, and the European Regional Development Fund.Small cardiac tissue engineering constructs show promise for limiting post-infarct sequelae in animal models. This study sought to scale-up a 2-cm 2 preclinical construct into a human-size advanced therapy medicinal product (ATMP; PeriCord), and to test it in a first-in-human implantation. The PeriCord is a clinical-size (12-16 cm 2) decellularised pericardial matrix colonised with human viable Wharton's jelly-derived mesenchymal stromal cells (WJ-MSCs). WJ-MSCs expanded following good manufacturing practices (GMP) met safety and quality standards regarding the number of cumulative population doublings, genomic stability, and sterility. Human decellularised pericardial scaffolds were tested for DNA content, matrix stiffness, pore size, and absence of microbiological growth. PeriCord implantation was surgically performed on a large non-revascularisable scar in the inferior wall of a 63-year-old male patient. Coronary artery bypass grafting was concomitantly performed in the non-infarcted area. At implantation, the 16-cm 2 pericardial scaffold contained 12·5 × 10 6 viable WJ-MSCs (85·4% cell viability; <0·51 endotoxin units (EU)/mL). Intraoperative PeriCord delivery was expeditious, and secured with surgical glue. The post-operative course showed non-adverse reaction to the PeriCord, without requiring host immunosuppression. The three-month clinical follow-up was uneventful, and three-month cardiac magnetic resonance imaging showed ~9% reduction in scar mass in the treated area. This preliminary report describes the development of a scalable clinical-size allogeneic PeriCord cardiac bioimplant, and its first-in-human implantation. La Marató de TV3 Foundation, Government of Catalonia, Catalan Society of Cardiology, "La Caixa" Banking Foundation, Spanish Ministry of Science, Innovation and Universities, Institute of Health Carlos III, and the European Regional Development Fund

Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis

Background: To date, there is little information regarding management of patients with infective endocarditis (IE) that did not undergo an indicated surgery. Therefore, we aimed to evaluate prognosis of these patients treated with a long-term antibiotic treatment strategy, including oral long term suppressive antibiotic treatment in five referral centres with a multidisciplinary endocarditis team.Methods: This retrospective, multicenter study retrieved individual patient-level data from five referral centres in Spain. Among a total of 1797, 32 consecutive patients with IE were examined (median age 72 years; 78% males) who had not undergone an indicated surgery, but received long-term antibiotic treatment (LTAT) and were followed by a multidisciplinary endocarditis team, between 2011 and 2019. Primary outcomes were infection relapse and mortality during follow-up.Results: Among 32 patients, 21 had IE associated with prostheses. Of the latter, 8 had an ascending aorta prosthetic graft. In 24 patients, a switch to long-term oral suppressive antibiotic treatment (LOSAT) was considered. The median duration of LOSAT was 277 days. Four patients experienced a relapse during follow-up. One patient died within 60 days, and 12 patients died between 60 days and 3 years. However, only 4 deaths were related to IE.Conclusions: The present study results suggest that a LTAT strategy, including LOSAT, might be considered for patients with IE that cannot undergo an indicated surgery. After hospitalization, they should be followed by a multidisciplinary endocarditis team

Cirugía Coronaria Sin Circulación Extracorpórea Versus Cirugía Coronaria Con Mini-Circulación Extracorpórea. Comparación de parámetros hematológicos y evolución postoperatoria

INTRODUCCIÓNLa incidencia de la cardiopatía isquémica es cada día mayor. El desarrollo de nuevas técnicas para su tratamiento, conlleva que los pacientes derivados para cirugía de revascularización presenten mayor edad, mayor comorbilidad y peores anatomías coronarias. El riesgo quirúrgico de esta población es, consecuentemente, cada vez mayor. La cirugía de revascularización miocárdica supone la intervención más frecuente realizada en todos los Servicios de Cirugía Cardíaca, siendo la revascularización con circulación extracorpórea (CEC) la técnica estándar más empleada. Los efectos deletéreos asociados a la CEC han llevado a la búsqueda de una nueva técnica que aúne las ventajas de la CEC, con una reducción de sus efectos negativos. La cirugía sin circulación extracorpórea (OPCABG), debido a su mayor dificultad técnica, presenta una progresiva menor aplicación en diversos centros. La cirugía con mini-circuitos (MECC) supone una nueva vía en la búsqueda de un tratamiento seguro, eficaz y reproducible. Los estudios realizados hasta el momento se muestran prometedores en este sentido. Su comparación con la cirugía OPCABG resulta de gran importancia, ya que permitirá conocer si esta nueva técnica supone una verdadera alternativa a las técnicas ya establecidas. MATERIAL Y MÉTODOSEntre enero de 2006 y diciembre de 2008 se llevó a cabo un estudio prospectivo y aleatorizado en 230 pacientes sometidos a revascularización miocárdica, divididos en dos grupos: OPCABG (n=117) y MECC (n=113) Se recogieron los datos demográficos, quirúrgicos y de evolución durante las primeras 48horas postoperatorias. La variable principal del estudio fue la hemodilución, la cual fue estudiada a través de las variaciones del hematocrito. Como variables secundarias se recogieron: i) la necesidad de transfusión, ii) las variaciones observadas en determinados parámetros biológicos (CPK, TnT, glucemia, leucocitos, plaquetas), y iii) la aparición de complicaciones (insuficiencia renal, fibrilación auricular, infarto, ictus, muerte). RESULTADOSEl EuroSCORE logístico (mortalidad esperada) era del 2,9% vs. 2,7%, p no significativa, en los grupos OPCABG y MECC respectivamente. El número de anastomosis distales fue de 2,78 vs. 2,84, p 0,5 (OPCABG vs. MECC). Se empleó la arteria mamaria interna en el 97% de los pacientes OPCABG y 98% de los pacientes MECC (p 0,4). Las cifras de hematocrito y hemoglobina presentaron diferencias estadísticamente significtivas a las 24 y 48 horas postoperatorias (hematocrito medio: 30,1% vs. 29%, p 0,04, y 29,8% vs. 28%, p 0,001) (hemoglobina media: 99,9g/l vs. 95,4g/l, p0,005, y 98,6g/l vs. 93,4g/l, p CONCLUSIONESLa cirugía con MECC es un procedimiento seguro y eficaz, presentando unos resultados semejantes a los obtenidos con la cirugía OPCABG. A pesar de existir diferencias estadísticamente significativas entre las cifras postoperatorias de hematocrito, estas no presentan la suficiente disparidad (no sobrepasan el límite establecido del 10% entre ambas) como para poder inferir que la hemodilución es diferente entre ambos grupos. Ambas técnicas son válidas para conseguir una reducción de la morbilidad asociada a la cirugía de revascularización miocárdica.INTRODUCTIONThe incidence of coronary artery disease is increasing rapidly. The development of new techniques for its treatment has resulted in older patients being referred for surgery, with higher comorbidy and worse condition of coronary arteries. Therefore, surgical risk in this population has increased. Coronary artery bypass grafting is the most frequent intervention performed in the cardiac surgery departments. Coronary revascularization with cardiopulmonary bypass is considered the gold standard technique. The adverse effects of cardiopulmonary bypass (CPB) made necessary the development of new strategies and surgical techniques with less negative effects. The limitations of off pump coronary revascularization (OPCABG) results primarily from its greater technical complexity, and the possible hemodynamic instability, so nowadays its use is decreasing. The mini extracorporeal circulation system (MECC) is a novel device which offers a new, safe and reproducible method for coronary revascularization. The comparison between this two techniques aimed to assess if MECC represents a real alternative to the off pump coronary revascularization. METHODSA prospective randomized trial was performed at our institution between January 2006 and December 2008. 230 patients underwent coronary artery bypass surgery were randomly divided into two groups: OPCABG (n=17) and MECC (n=113). We collected demographic, operative and postoperative (48 hours) data. Variations in hemodilution degree and hematocrit values were the primary end points of the study. Transfusion rates, biological markers (CPK and T-troponin), haematological factors (glucose, platelets, leukocytes), and postoperative complications such as renal failure, atrial fibrillation, myocardial infarction, stroke and death were studied as secondary end points. RESULTSLogistic EuroSCORE was 2,9% vs. 2,7%, p n.s., in OPCABG and MECC groups respectively. Number of grafts was 2,78 vs 2,84, p 0,5 (OPCABG vs. MECC). The internal mammary artery was used in 97% of OPCABG patients, and in 98% of MECC patients (p 0,4). Analysis of hematocrit and haemoglobin values between groups presented significant statistic differences at 24 and 48 hours postoperatively (mean hematocrit: 30,1% vs. 29%, p 0,04, and 29,8% vs. 28%, p 0,001) (mean haemoglobin: 99,9g/l vs. 95,4g/l, p0,005, and 98,6g/l vs. 93,4g/l, p CONCLUSIONCoronary artery revascularization with mini extracorporeal systems is a safe procedure and is associated with similar results as observed with off pump coronary revascularization. Despite being significant statistic differences between postoperative hematocrit values, those differences do not reach the pre-stablished cut-off value of 10%, so we can infer that the hemodilution is similar in both groups. Both techniques, OPCABG and MECC, are associated with reduced morbidity in coronary revascularization

Cirugía coronaria sin circulación extracorpórea versus cirugía coronaria con mini-circulación extracorpórea : comparación de parámetros hematológicos y evolución postoperatoria /

Descripció del recurs: 5 novembre 2010INTRODUCCIÓN La incidencia de la cardiopatía isquémica es cada día mayor. El desarrollo de nuevas técnicas para su tratamiento, conlleva que los pacientes derivados para cirugía de revascularización presenten mayor edad, mayor comorbilidad y peores anatomías coronarias. El riesgo quirúrgico de esta población es, consecuentemente, cada vez mayor. La cirugía de revascularización miocárdica supone la intervención más frecuente realizada en todos los Servicios de Cirugía Cardíaca, siendo la revascularización con circulación extracorpórea (CEC) la técnica estándar más empleada. Los efectos deletéreos asociados a la CEC han llevado a la búsqueda de una nueva técnica que aúne las ventajas de la CEC, con una reducción de sus efectos negativos. La cirugía sin circulación extracorpórea (OPCABG), debido a su mayor dificultad técnica, presenta una progresiva menor aplicación en diversos centros. La cirugía con mini-circuitos (MECC) supone una nueva vía en la búsqueda de un tratamiento seguro, eficaz y reproducible. Los estudios realizados hasta el momento se muestran prometedores en este sentido. Su comparación con la cirugía OPCABG resulta de gran importancia, ya que permitirá conocer si esta nueva técnica supone una verdadera alternativa a las técnicas ya establecidas. MATERIAL Y MÉTODOS Entre enero de 2006 y diciembre de 2008 se llevó a cabo un estudio prospectivo y aleatorizado en 230 pacientes sometidos a revascularización miocárdica, divididos en dos grupos: OPCABG (n=117) y MECC (n=113) Se recogieron los datos demográficos, quirúrgicos y de evolución durante las primeras 48horas postoperatorias. La variable principal del estudio fue la hemodilución, la cual fue estudiada a través de las variaciones del hematocrito. Como variables secundarias se recogieron: i) la necesidad de transfusión, ii) las variaciones observadas en determinados parámetros biológicos (CPK, TnT, glucemia, leucocitos, plaquetas), y iii) la aparición de complicaciones (insuficiencia renal, fibrilación auricular, infarto, ictus, muerte). RESULTADOS El EuroSCORE logístico (mortalidad esperada) era del 2,9% vs. 2,7%, p no significativa, en los grupos OPCABG y MECC respectivamente. El número de anastomosis distales fue de 2,78 vs. 2,84, p 0,5 (OPCABG vs. MECC). Se empleó la arteria mamaria interna en el 97% de los pacientes OPCABG y 98% de los pacientes MECC (p 0,4). Las cifras de hematocrito y hemoglobina presentaron diferencias estadísticamente significtivas a las 24 y 48 horas postoperatorias (hematocrito medio: 30,1% vs. 29%, p 0,04, y 29,8% vs. 28%, p 0,001) (hemoglobina media: 99,9g/l vs. 95,4g/l, p0,005, y 98,6g/l vs. 93,4g/l, p 0,001) (grupo OPCABG vs. MECC respectivamente). La tasa de transfusión fue comparable entre ambos grupos (57% vs. 61%, p 0,5, OPCABG vs. MECC respectivamente). El pico de creatinquinasa fue de 633±526 vs. 899±1006 (p 0,01), y el de troponina T 0,37±0,57 vs. 0,32±0,5 (p 0,5, OPCABG vs. MECC respectivamente). No se encontraron diferencias en la aparición de insuficiencia renal, infarto, inestabilidad hemodinámica y fibrilación auricular. Esta última fue la complicación más frecuente en ambos grupos (25% vs. 23%, p 0,7, OPCABG vs. MECC respectivamente). Dos pacientes requirieron hemodiafiltración postoperatoria, ambos pertenecientes al grupo OPCABG. Cinco pacientes requirieron la colocación de balón de contrapulsación, 4 en el grupo OPCABG y 1 en el MECC (p 0,8). No se produjo ningún caso de muerte. CONCLUSIONES La cirugía con MECC es un procedimiento seguro y eficaz, presentando unos resultados semejantes a los obtenidos con la cirugía OPCABG. A pesar de existir diferencias estadísticamente significativas entre las cifras postoperatorias de hematocrito, estas no presentan la suficiente disparidad (no sobrepasan el límite establecido del 10% entre ambas) como para poder inferir que la hemodilución es diferente entre ambos grupos. Ambas técnicas son válidas para conseguir una reducción de la morbilidad asociada a la cirugía de revascularización miocárdica.INTRODUCTION The incidence of coronary artery disease is increasing rapidly. The development of new techniques for its treatment has resulted in older patients being referred for surgery, with higher comorbidy and worse condition of coronary arteries. Therefore, surgical risk in this population has increased. Coronary artery bypass grafting is the most frequent intervention performed in the cardiac surgery departments. Coronary revascularization with cardiopulmonary bypass is considered the gold standard technique. The adverse effects of cardiopulmonary bypass (CPB) made necessary the development of new strategies and surgical techniques with less negative effects. The limitations of off pump coronary revascularization (OPCABG) results primarily from its greater technical complexity, and the possible hemodynamic instability, so nowadays its use is decreasing. The mini extracorporeal circulation system (MECC) is a novel device which offers a new, safe and reproducible method for coronary revascularization. The comparison between this two techniques aimed to assess if MECC represents a real alternative to the off pump coronary revascularization. METHODS A prospective randomized trial was performed at our institution between January 2006 and December 2008. 230 patients underwent coronary artery bypass surgery were randomly divided into two groups: OPCABG (n=17) and MECC (n=113). We collected demographic, operative and postoperative (48 hours) data. Variations in hemodilution degree and hematocrit values were the primary end points of the study. Transfusion rates, biological markers (CPK and T-troponin), haematological factors (glucose, platelets, leukocytes), and postoperative complications such as renal failure, atrial fibrillation, myocardial infarction, stroke and death were studied as secondary end points. RESULTS Logistic EuroSCORE was 2,9% vs. 2,7%, p n.s., in OPCABG and MECC groups respectively. Number of grafts was 2,78 vs 2,84, p 0,5 (OPCABG vs. MECC). The internal mammary artery was used in 97% of OPCABG patients, and in 98% of MECC patients (p 0,4). Analysis of hematocrit and haemoglobin values between groups presented significant statistic differences at 24 and 48 hours postoperatively (mean hematocrit: 30,1% vs. 29%, p 0,04, and 29,8% vs. 28%, p 0,001) (mean haemoglobin: 99,9g/l vs. 95,4g/l, p0,005, and 98,6g/l vs. 93,4g/l, p 0,001) (OPCABG vs. MECC). Transfusion rates were similar between groups (57% vs. 61%, p 0,5, OPCABG vs. MECC). Peak CPK was 633±526 vs. 899±1006 (p 0,01), and peak T-troponin was 0,37±0,57 vs. 0,32±0,5 (p 0,5, OPCABG vs. MECC). There were no differences in postoperative complications: renal failure, myocardial infarction, hemodynamic instability and atrial fibrillation. The latter was the most frequent postoperative complication in both groups (25% vs. 23%, p 0,7, OPCABG vs. MECC). Two patients required postoperative haemodialysis, both from the OPCABG group. Five patients required postoperative intra aortic balloon pump therapy; four were from the OPCABG group and one from the MECC group (p 0,8). There were no deaths during the study. CONCLUSION Coronary artery revascularization with mini extracorporeal systems is a safe procedure and is associated with similar results as observed with off pump coronary revascularization. Despite being significant statistic differences between postoperative hematocrit values, those differences do not reach the pre-stablished cut-off value of 10%, so we can infer that the hemodilution is similar in both groups. Both techniques, OPCABG and MECC, are associated with reduced morbidity in coronary revascularization

Hidatidosis cardíaca primaria: quiste hidatídico en aurícula derecha con diseminación pulmonar

La hidatidosis es una enfermedad parasitaria producida por la larva del cestodo Echinococcus. El quiste hidatídico, la forma más habitual de presentación, es producida por la especie E. granulosus. la afectación cardíaca es muy rara, produciéndose en aproximadamente el 0,5–2% de los casos. El 65% de los casos de hidatidosis cardíaca se localizan en las cavidades izquierdas. Presentamos el caso de un paciente en el que la primera localización de la enfermedad fue la aurícula derecha (Ad), junto con diseminación pulmonar quística. La localización exclusiva en las cavidades cardíacas derechas y en la arteria pulmonar constituye una presentación clínica inusual. se ha revisado la bibliografía, prestando especial interés en la importancia de las técnicas de imagen disponibles en la actualidad para su diagnóstico, así como la necesidad de un tratamiento quirúrgico precoz para evitar sus posibles complicaciones

Valoración a medio plazo de la insuficiencia tricuspídea funcional tras anuloplastia con anillo rígido tridimensional

Introducción y objetivos: La insuficiencia tricuspídea funcional significativa conlleva una mayor morbimortalidad si no se corrige durante la cirugía valvular izquierda o si reaparece en el seguimiento. La anuloplastia tricuspídea mediante técnicas de sutura presenta una alta tasa de recurrencia de insuficiencia tricuspídea. Actualmente se prefieren las técnicas con anillo protésico, ya que presentan resultados más duraderos en el seguimiento. Los objetivos de este estudio son evaluar los resultados ecocardiográficos a medio plazo de la anuloplastia tricuspídea con anillo rígido tridimensional, así como analizar los factores predictores de recurrencia de insuficiencia tricuspídea significativa. Métodos: Se recogieron los datos clínicos y ecocardiográficos de 260 pacientes intervenidos de anuloplastia tricuspídea mediante anillo rígido tridimensional en nuestro centro. Se llevó a cabo el análisis multivariante mediante regresión logística para determinar los factores de riesgo de reaparición de insuficiencia tricuspídea moderada-grave. Resultados: Tras una mediana de seguimiento de 16 meses (3,9-34,5), 220 pacientes (84,62%) presentaban un ecocardiograma de control. La persistencia/recurrencia de insuficiencia tricuspídea grave fue del 5,0%. Los factores de riesgo asociados a la persistencia/recurrencia de insuficiencia tricuspídea significativa fueron: hipertensión pulmonar grave en el seguimiento (OR 337,91; IC 95%: 34,60-3.300,07; p < 0,001) e insuficiencia cardiaca derecha postoperatoria (OR 1,02; IC 95%: 1,003-1,037; p = 0,021). La función ventricular izquierda conservada (OR 0,96; IC 95%: 0,927-0,993; p = 0,018) y la cirugía mitral (OR 0,97; IC 95%: 0,960-0,990; p = 0,001) presentaron un papel protector. Conclusiones: La anuloplastia tricuspídea mediante anillo rígido tridimensional corrige de manera efectiva la insuficiencia tricuspídea funcional, con una baja frecuencia de persistencia/recurrencia de insuficiencia tricuspídea grave

Mitochondrial genetic effect on atrial fibrillation: A case-control study

Atrial fibrillation (AF) is a common arrhythmia in the general population and following cardiac surgery. The influence of mitochondrial genomics on AF pathogenesis is not fully understood. We analyzed mitochondrial variables from 78 human atrial samples collected from cardiac surgeries in the following groups: 1) permanent preoperative AF; 2) preoperative sinus rhythm (SR) with postoperative AF; and 3) pre-/postoperative SR. Haplogroup H appeared offer protection against, and haplogroup U predispose to permanent AF. mtDNA content was higher in group 2 than in 3. These findings contribute to a better understanding of the influence of mitochondria on AF pathogenesis.The study was supported by the Ministry of Economy and Competitiveness, Spain for the sample preparation at the Cardiovascular Research Centre and CIBERCV, Spain (SAF2014-58286-C2-1-R)

Medium-term assessment of functional tricuspid regurgitation after annuloplasty using a three-dimensional rigid ring Valoración a medio plazo de la insuficiencia tricuspídea funcional tras anuloplastia con anillo rígido tridimensional

Significant functional tricuspid regurgitation is associated with a high morbidity and mortality if not repaired during left heart-valve surgery, or if it recurs during the follow-up. Classic tricuspid annuloplasty with suture techniques has a high rate of tricuspid regurgitation recurrence. Annuloplasty techniques with prosthetic rings are currently preferred for this condition, since they have longer-lasting results during the follow-up. The objectives of this study are to assess the medium-term echocardiographic outcomes of tricuspid annuloplasty using a three-dimensional rigid ring, and to determinate the predictive factors for recurrence of significant tricuspid regurgitation after annuloplasty. Variables were collected from a total 260 tricuspid annuloplasties with a three-dimensional rigid ring performed in our centre, along with the clinical and echocardiographic follow-up data. A multivariate regression analysis was carried out in order to establish the risk factors predisposing to significant tricuspid regurgitation during the follow-up. After a median follow-up time 16 months (3.9-34.5), 220 patients (84.62%) had a control echocardiogram. Persistent/recurrent severe tricuspid regurgitation occurred in 5.0%. Risk factors for significant tricuspid regurgitation after annuloplasty were: Severe pulmonary hypertension at follow-up (OR 337.91; 95% CI: 34.60-3300.07; P<.001) and post-operative right heart failure (OR 1.02; 95% CI: 1.003-1.037; P=.021). Preserved left ventricle function (OR 0.96; 95% CI: 0.927-0.993; P=.018) and concomitant mitral surgery (OR 0.97; 95% CI: 0.960-0.990; P=.001) emerged as protector factors. Tricuspid annuloplasty using a three-dimensional rigid ring is an effective procedure for correcting secondary tricuspid regurgitation, with a low rate of persistent or recurrent significant tricuspid regurgitation during the followup